EE9900477A - Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity - Google Patents

Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity

Info

Publication number
EE9900477A
EE9900477A EEP199900477A EE9900477A EE9900477A EE 9900477 A EE9900477 A EE 9900477A EE P199900477 A EEP199900477 A EE P199900477A EE 9900477 A EE9900477 A EE 9900477A EE 9900477 A EE9900477 A EE 9900477A
Authority
EE
Estonia
Prior art keywords
activity
compositions
compounds
treatment
serine protease
Prior art date
Application number
EEP199900477A
Other languages
Estonian (et)
Other versions
EE04055B1 (en
Inventor
Rueywen Wang Vivian
J. Church Timothy
Scott Cutshall Neil
R. Gangloff Anthony
E. Jenkins Thomas
S. Linsell Martin
Litvak Joane
D. Rice Kenneth
R. Spencer Jeffrey
Original Assignee
Axys Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharmaceuticals, Inc. filed Critical Axys Pharmaceuticals, Inc.
Publication of EE9900477A publication Critical patent/EE9900477A/en
Publication of EE04055B1 publication Critical patent/EE04055B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP199900477A 1997-04-07 1997-12-01 Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity, and their use EE04055B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83367497A 1997-04-07 1997-04-07
PCT/US1997/021849 WO1998045275A1 (en) 1997-04-07 1997-12-01 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity

Publications (2)

Publication Number Publication Date
EE9900477A true EE9900477A (en) 2000-06-15
EE04055B1 EE04055B1 (en) 2003-06-16

Family

ID=25264996

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900477A EE04055B1 (en) 1997-04-07 1997-12-01 Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity, and their use

Country Status (16)

Country Link
EP (1) EP1019382A1 (en)
JP (1) JP2001519806A (en)
KR (1) KR20010006119A (en)
CN (1) CN1251579A (en)
AU (1) AU752064B2 (en)
CA (1) CA2285454A1 (en)
EE (1) EE04055B1 (en)
HU (1) HUP0001522A3 (en)
LT (1) LT4704B (en)
LV (1) LV12495B (en)
NO (1) NO314183B1 (en)
NZ (1) NZ500029A (en)
PL (1) PL336233A1 (en)
SI (1) SI20115A (en)
SK (1) SK136799A3 (en)
WO (1) WO1998045275A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU1608399A (en) * 1997-11-26 1999-06-15 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
WO1999026932A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. By amidino group substituted heterocyclic derivatives and their use as anticoagulants
GT199900167A (en) * 1998-10-01 2001-03-21 NEW BIS-BENZIMIDAZOLES.
AU1099000A (en) * 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
US6541486B1 (en) * 1999-06-04 2003-04-01 Elan Pharma International Ltd. Bis-benzimidazole compounds and analogs thereof for inhibiting cell death
DE19953899A1 (en) * 1999-11-10 2001-05-17 Boehringer Ingelheim Pharma Carboxamide-substituted benzimidazole derivatives, process for their preparation and their use as medicaments
AU2001231030A1 (en) * 2000-01-20 2001-07-31 Amgen Inc Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
DE10048715A1 (en) * 2000-09-30 2004-05-19 Grünenthal GmbH Use of amino acid for the treatment of pain
WO2002070491A1 (en) * 2001-03-01 2002-09-12 Shionogi & Co., Ltd. Nitrogenous heteroaromatic ring derivative having hiv integrase inhibitory activity
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
DE102011111991A1 (en) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh New cyclosporin derivatives
KR101892330B1 (en) * 2011-11-29 2018-08-27 페로스피어 파마슈티컬스 인코포레이티드 Anticoagulant reversal agents
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN113727984B (en) * 2019-05-21 2024-03-15 浙江海正药业股份有限公司 Macrocyclic derivatives, preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105837A (en) * 1961-10-20 1963-10-01 Upjohn Co 2, 2'-alkylenebisbenzimidazoles
US3210370A (en) * 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
WO1995008540A1 (en) * 1993-09-22 1995-03-30 The Wellcome Foundation Limited Bis(amidinobenzimidazolyl)alkanes as antiviral agents
US6815461B1 (en) * 1994-01-20 2004-11-09 The University Of North Carolina At Chapel Hill Method of inhibiting retroviral integrase
US5693515A (en) * 1995-04-28 1997-12-02 Arris Pharmaceutical Corporation Metal complexed serine protease inhibitors

Also Published As

Publication number Publication date
SI20115A (en) 2000-06-30
NO994858D0 (en) 1999-10-06
AU5895098A (en) 1998-10-30
LV12495B (en) 2001-01-20
CN1251579A (en) 2000-04-26
HUP0001522A2 (en) 2001-05-28
CA2285454A1 (en) 1998-10-15
PL336233A1 (en) 2000-06-19
EE04055B1 (en) 2003-06-16
WO1998045275A1 (en) 1998-10-15
AU752064B2 (en) 2002-09-05
NO994858L (en) 1999-12-06
LT99131A (en) 2000-04-25
NO314183B1 (en) 2003-02-10
SK136799A3 (en) 2000-07-11
JP2001519806A (en) 2001-10-23
LT4704B (en) 2000-09-25
NZ500029A (en) 2001-02-23
EP1019382A1 (en) 2000-07-19
KR20010006119A (en) 2001-01-26
LV12495A (en) 2000-06-20
HUP0001522A3 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
EE9900036A (en) Novel compounds and compositions for the treatment of diseases associated with tryptase activity
EE9900477A (en) Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity
BR9712544B1 (en) SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES
ID22878A (en) ACTIVE COMPOSITION THERAPY
ATE417602T1 (en) AGENTS FOR THE TREATMENT OF DISEASES OF THE ESOPHAUS
TR199501137A2 (en) Therapeutically active ingredients
DK0979240T3 (en) serine protease
PL360493A1 (en) Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus
EE04156B1 (en) Sulfonamides for the treatment of endothelin-mediated diseases
EE200300214A (en) Sulfonamides for the treatment of endothelin-mediated diseases
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
DE69836008D1 (en) COMPOSITION AND TREATMENT AGENT
IS5504A (en) Composition active in the treatment of impotence
HUP0101699A3 (en) Benzoxazinones/benzothiazinones as serine protease inhibitors and pharmaceutical compositions containing the same
DE69812784D1 (en) Composition for the prevention and elimination of plant diseases
FI964342A0 (en) Halomethylamides as IL-1beta protease inhibitors
PT900563E (en) PRODUCTION OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF EDEMA AND VENOUS DISEASES
ID29966A (en) SULFONYLOKSAZOLAMINA-SULFONYLOKSAZOLAMINA AS ACTIVE COMPOUNDS OF THERAPY
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
DE69913380D1 (en) COMPOSITION FOR THE TREATMENT OF PERIODONTAL DISEASES
NO20004920D0 (en) Use of protease inhibitors for the treatment of skin damage
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
DE60043648D1 (en) MEDICAMENTS FOR THE TREATMENT OF PERIODONTAL DISEASES
DE69927796D1 (en) Improvement of the manufacturing process of footwear
BR9608978A (en) Serine protease inhibitor derived from imidazo [1,5a] pyridine pharmaceutical composition and use of protease inhibitor

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

MM4A Lapsed by not paying the annual fees

Effective date: 20031201